eTheRNA Immunotherapies
28 articles with eTheRNA Immunotherapies
-
Russian researchers announced a new Sputnik V vaccine against the Delta and Omicron variants of COVID-19, AB Science files for conditional marketing approval of its ALS drug in the EU and much more.
-
Money is now flowing into promising platforms for prostate cancer from AdvanCell, mRNA therapeutics from eTheRNA, hepatitis from Bluejay and more.
-
mRNA Leading Expert Kenneth Chien and Novalis LifeSciences’ Marijn Dekkers Investing EUR 39M Series B2 Financing in mRNA Technology Platform Company eTheRNA
8/23/2022
eTheRNA, a leading mRNA technologies company, announced that it has raised €39M in a Series B2 financing to expand investment in its integrated mRNA technology platform and further pursue its new initiatives for a partnership-driven business strategy.
-
Biopharma and life sciences organizations from across the globe provide updates on their businesses and pipelines.
-
eTheRNA Announces Relocation and Expansion of R&D Facility
4/5/2022
eTheRNA immunotherapies NV, an mRNA technology discovery and development company with a full platform of integrated capabilities, is pleased to announce the relocation of its R&D group to a new and larger site in Gent, Belgium.
-
eTheRNA Immunotherapies to Host Key Opinion Leader Webinar on mRNA-Lipid Nanoparticles for Cancer ImmunotherapyWednesday, March 2 at 10am ET / 3pm GMT / 4pm CET
2/28/2022
eTheRNA immunotherapies NV (‘eTheRNA’), an mRNA technology discovery and development company with a full platform of integrated capabilities, today announced that it will host a key opinion leader (KOL) webinar on mRNA-lipid nanoparticles (LNP) for cancer immunotherapy on Wednesday, March 2, 2022 at 10am ET / 3pm GMT / 4pm CET.
-
BioSpace Movers & Shakers, July 30, 2021
7/30/2021
Biopharma and life science companies strengthen their leadership teams and boards with these Movers & Shakers. -
Biopharma and life sciences companies from across the globe provide updates on their business practices and pipelines.
-
Biopharma and life sciences companies from across the globe provide updates on their businesses and pipelines.
-
Biopharma and life sciences companies from across the globe provide updates on their businesses and pipelines.
-
BioSpace Movers & Shakers, March 12
3/12/2021
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers. -
BioSpace Movers & Shakers, March 5
3/5/2021
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers. -
Biopharma and life sciences companies from across the globe provide updates on their businesses and pipelines.
-
Biopharma and life sciences companies from across the globe provide updates on their business and pipelines.
-
BioSpace Movers & Shakers, Oct. 9
10/9/2020
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers. -
BioSpace Global Roundup, June 18
6/18/2020
Biopharma and life sciences companies from across the globe provide updates on their pipelines and business operations. -
eTheRNA Raises EUR 34 Million in Series B Financing to Accelerate Multiple mRNA Therapeutic Development Programs Through to Clinical Proof of Concept
6/16/2020
eTheRNA immunotherapies NV, a clinical-stage company developing immunotherapies from its proprietary mRNA TriMix platform for the treatment of cancer and infectious diseases, announced that it has successfully raised Euro 34 million in a Series B equity financing round.
-
BioSpace Global Roundup, April 23
4/23/2020
Biopharma and life sciences groups from across the globe provide updates on their business and pipelines. -
BioSpace Global Roundup, March 26
3/26/2020
Pharma and life sciences companies from across the globe provide updates on their pipelines and business practices. -
eTheRNA Launches an International Consortium and Starts Development of Cross-strain Protective CoV-2 mRNA Vaccine for High Risk Populations
3/24/2020
eTheRNA Immunotherapies nv announced that a consortium has been formed with North American and European partners to develop a novel mRNA vaccine against CoV-2 and preclinical development has started.